COMP <GO>
IONS vs LLY // NET PROFIT MARGIN
Ionis Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: IONS 3
— LLY 11
▲ NET PROFIT MARGIN LEADER: LLY
LAST: $43.52 (-1.96%) • MKT CAP: $7.38B
net-margins
-40.40%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
net-margins
31.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IONS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IONS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 83.64% | +12.36 | IONS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.90% | 32.36% | -53.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.34% | 2.30% | -6.64 | LLY | /fcf-yield <GO> |
| Operating Margin | -40.40% | 40.21% | -80.61 | LLY | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -40.40% | 31.90% | -72.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 33.80% | 45.51% | -11.71 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.08 | 9.29 | -8.21 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.77% | +0.43 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.1 | 77.9 | -34.74 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 0.51 | +0.58 | IONS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 26.3x | -4.25 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.38B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IONS REV | LLY REV | IONS GROSS % | LLY GROSS % | IONS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $943.7M | $65.18B | 98.3% | 83.0% | -$320.0M | $16.81B |
| FY 2024 | $705.1M | $45.04B | 98.4% | 81.3% | -$546.2M | $8.82B |
| FY 2023 | $787.6M | $34.12B | 44.0% | 79.3% | -$343.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IONS // BETA 1.09
LLY // BETA 0.51